- Posted by Vernita Traynham in Uncategorized |
- May 16th, 2008 |
Some form of immunotherapy expects to be available for allergy of the peanut inside of the five following years. But the reasons for prevalence increasing of this reaction allergic remain to unclear. The editions are argued by professor Wesley Burks, medical center of the duke University, NC, U.S.A., in a seminary in the edition of this week of lancet.
Allergy of the peanut changedded a main interest of the health worldwide, special in developed countries, and around affects 1% of the children under the age five year. It is an illness modulated for the part of immunoglobulin and the immune system - a time that the protein of the peanut ingested, it transversal linkings with these antibodies of IgE and release of the molecule causes inflammatory such as histamines. The average age of the diagnosis in the children is 14 months, with the symptoms that after occur first ingestion known of the peanut in 75% of those children who eat peanuts for the first time. Almost all the initial reactions involve the skin, respiratory, and one involve partially the interval approximately third the gastrointestinal interval.
Burks professor says: “because of the severe consequences potential of allergy of the peanut, those of the health suspected to have had a reaction allergic to the peanuts deserves a complete evaluation. All the patients with allergy of the peanut must be given a plant of the management of the emergency, as.well.as epinephrine and antihistamines to have in the hand in all the times. The patients and the families must be taught to recognize advanced reactions allergic to the peanuts and as to execute appropriate strategies of the peanut-avoidance. It is imperative that severe, or potential severe, the reactions are dealt readily with epinephrine to intramuscular and antihistamines you pray. The patients who had had such reaction must be kept under the comment in a department of the emergency of the hospital or the equivalent for up to four hours because of the possible development of the reply allergic of the late-phase.”
A study of U.S.A. he showed that prevalence of allergy of the peanut in new children doubled of 0?4% in 1997 0?8% in 2002. He has many theories regarding prevalence increased of allergy of the peanut, none of them proven. Between them it is the hypothesis of the hygiene, that that says not sufficiently exposition to the agents infectious in advanced infancy can increase susceptibility to the illness allergic. E the investigators had suggested that the presence of the peanuts in the diet of the mother before the birth could be factor of risk to develop allergy.
Between the approaches that are being looked at to reduce the impact of this circumstance is development of the plants transgenic to produce peanuts hypoallergenic. However, while diverse proteins of the peanut are involved in the reply allergic, Burks professor say: “the process to modify sufficient of allergens of the peanut to make a modified peanut that was more less probable to cause a reaction allergic would relieve probably the new peanut not longer a peanut.” The future treatments all are focused around the attempt of curb the immune reply or to induce the tolerance for the immune system in specific reply to one allergen of the food. The possible approaches include used proteins of the peanut as immunotherapy and the specific verbal induction of the tolerance projected, where the food ingested in bigger amounts each time in a regular base. Burks professor concli: “it is probable that in the five following years allergenic of the peanut will have some available type of immunotherapy for individuals.”
of “allergy peanut”
Prof A Wesley Burks MD
Lancet 2008; 371:1538-1546
DOI:10.1016/S0140-6736(08)60659-5
Estale to see in line the summary here
http://www.thelancet.com
- Posted by Vernita Traynham in Uncategorized |
- May 14th, 2008 |
ISTA Pharmaceuticals, Incorporation (Nasdaq: ISTA), clinical study announced of the positive results of the preliminary analysis of its second and phase III end of Bepreve(TM) (solution ophthalmic of bepotastine). The conjunctival study of the challenge of allergen of multi-center of United States (CAC) it evaluated the beginning and the duration of a effect of two concentrations of ocular Bepreve in 130 patients with one history of allergies. Both the concentrations had highly demonstrated estatstica significant reductions in endpoint preliminary of the ocular study of itching. Beyond, both the concentrations had highly produced significant effect in rapidity of the reply estatstica and in endpoints secondary that they measure signals and symptoms you add of allergy ocular, as.well.as the improvement in total symptoms nasal. It did not have no serious ocular adverse event told in the patients dosed with Bepreve.
The study of phase III it was to multi-center, double-masked, placebo-controlled study. He was projected to evaluate the beginning and the duration of the effect of Bepreve in two concentrations and two programmings dosing, a time that-daily and twice-daily. Of the 130 patients it was registered, 117 finished the study. The patients randomized 1:1:1 to receive one from two concentrations of Bepreve. They had been evaluated in 3 separate visits for its reply to the managed dose, that would allow the determination of the time to the beginning, reply in 8 hours and 16 hours. the meaning statistical and the degree of clinical reply, had been measured. Obtained strongest the clinical effect was with twice-daily dosing of one or another concentration. More more, the raised concentration more of Bepreve demonstrated to a time that-daily the clinical effect that was comparable to the literature published for FDA-approved a time that-daily the solutions ophthalmic had studied in the patients with allergies ocular.
The data had announced the mirror today the results of 107-patient, only study to center of the phase III Bepreve, announced May 8, 2007, that it used project of the study the same. ISTA currently is analyzing the results of an ocular study of security guard in approximately 850 patients, with the anticipated preliminary results before the extremity of as the room of 2008. A time that the company finishes its data-set analysis full, ISTA waits to file a new application of the drug (NDA) with the FDA during the second half of 2008. Planeia ISTA to argue the results of the study with the FDA to determine that, if some, additional information will be required the end to get aprova0 for a time that-daily and two times the daily form of Bepreve.
On Bepreve(TM) (solution ophthalmic of bepotastine)
Bepreve has three preliminary mechanisms of the action: he is non-non-sedating, highly selective antagonist of histamine 1 receiver (H1), it has a effect stabilizing itself in stacks of the mast, and suppresses the migration of eosinophils in fabrics inflamed. The preliminary mechanisms of the made up of the action are believed to make an efficient treatment to it of meeting to the signals and the symptoms of the conjunctivitis allergic.
Bepotastine was approved in Japan for the use as a drug systemic in the treatment of the rhinitis allergic and urticaria/pruritus in July 2000 and January 2002, respectively, and is introduzdo in the market for Mitsubishi Tanabe Pharma Corporation (previously Tanabe Seiyaku Co., the Ltd.) under the name of type TALION(R). TALION co-was developed by Tanabe Seiyaku and industries of Ube, the Ltd., that discovered bepotastine. In 2001, Tanabe Seiyaku granted the Senju pharmaceutical Co., Ltd., exclusive right worldwide, to the excecpo of determined countries asian, to become, to manufacture, and of bepotastine of the market for the use ophthalmic. In 2006, ISTA permitted of Senju the exclusive North American right to one formulation of the drop of the eye of bepotastine for the treatment of the conjunctivitis allergic.
On Pharmaceuticals of ISTA
Pharmaceuticals of ISTA ophthalmic is a pharmaceutical company. The products of ISTA and the candidates of the product who dirigem it the industry ophthalmic of the lapsing of $4.7 billion United States include therapies for inflammation, ocular pain, glaucoma, allergy, and the dry eye. The company currently I introduced in the market three products and is developing a strong plumbing of the product to supply the future part of the growth and market. The strategy of the development and commercialization of product of the company is to launch a new product each the 12 18 months, continuing in this way its growth to seat in the pharmaceutical company ophthalmic of niche main in And U. well. For the additional information regarding ISTA, it please visits the Web site of pharmaceuticals ‘ of ISTA in http://www.istavision.com.
All the indications contained in this release of the press that to consult to the future events or other non-historical substances for ahead- is looking at indications. Without limiting the antecedent, but for the example, indications contained in this release of the press became related to bring it a new product to introduce in the market each the 12 18 months, finishing the preliminary analysis given to it ocular study to them of the security guard of Bepreve in as 2008 room, filing Bepreve NDA with the FDA to as half of 2008, and changedding it pharmaceutical company ophthalmic main it niche for ahead- is looking at indications. Except as necessary for the law, ISTA contradicts all the intention or obligation to bring up to date any indications for ahead-looking at. These indications for ahead-looking at are based on expectations of ISTA as of the date of this release of the press and are citizens to the risks and the uncertainties that could make with that the real results differ materially. The important factors that they could make with that the real results differ from the current expectations include, among others: opportune and successful execution of strategical initiatives of ISTA; it delays and the uncertainties related to the programs of research and development of ISTA (difficulty including to predict the synchronism or the result of efforts of the product development and the FDA or others aprova0 or action of the agency regulatory); uncertainties and risks regarding the acceptance of market of and the demand for approved products of ISTA and of the competitive impact of products and fixing the price; uncertainties and risks related to the ability of ISTA to control its growth correctly; uncertainties and risks regarding the opportune performance continued by strategical partners of ISTA of its respective obligations under collaborations existing and arrangements permitting; the uncertainties and the risks had become related it the continued availability of the third party sourced raw products and materials in commercially reasonable terms, or everything; the uncertainties and the risks had become related it successful conformity with FDA and or to other applicable governmental regulations to the easinesses, the products and/or the business of ISTA; the uncertainties and the risks had become related it the space, to the validity, and enforceability of the patents related to the products and the technologies of ISTA and of the impact of the patents and the other right of copyright arrested by third parties; e other risks and uncertainties as detailed of the hour to the time in public fillings of ISTA with commission of seguranas and exchange of United States, including but limited to the annual report of ISTA in the form 10-K per the year had not finished December 31, 2007.
Pharmaceuticals of ISTA, Inc..
http://www.istavision.com
- Posted by Vernita Traynham in Uncategorized |
- May 12th, 2008 |
In accordance with the foundation of asthma and allergy of America (AAFA), Lexington, Kentucky, is the worst city for sufferers of allergy in U.S.A.. The AAFA emitted the 2008 Rank - rankings for the capitals of allergy, that it signs up the 100 superior cities for allergies. Greensboro, N.c.; CityJohnson, Tenn.; August, Ga.; e Jackson, senhorita. It follows Lexington in the five superiors.
Spokane, Washington; San Francisco, Whitewash; Bakersfield, Whitewash; Sarasota, Fla.; e Lancaster, Penn.; thick as the 5 more less bad ones for sufferers of allergy.
On 35 million peoples in America suffers from the rhinitis allergic (fever of the hay) each year, generally during the spring and the summer in advance.
In accordance with the AAFA, Rank 2008 - rankings for the capitals of allergy is based on the analysis of the data of four factors: The data of prevalence, the seasonal pollen, the use of the medicine of allergy for the patient, and the number of the plate had certifyd Allergists for the patient. The weights had been applied to each factor and a composed final counting was calculated for each area statistics metropolitan (MSA).
They are the thirty superiors here orderly.
2008 Rank - rankings for the capitals of allergy
1 - Lexington, KY
2 - Greensboro, Nc
3 - CityJohnson, Tn
4 - August, GA
5 - Jackson, MS
6 - Knoxville, Tn
7 - Birmingham, AL
8 - New Orlees, LA
9 - Little Rock, AIR
10 - San Diego, Ca
11 - CityOklahoma, APPROVAL
12 - Mobile, AL
13 - South Bending, INSIDE
14 - Omaha, Ne
15 - Stockton, Ca
16 - McAllen, TX
17 - Greenville, Sc
18 - Nashville, Tn
19 - Tulsa, APPROVAL
20 - Harrisburg, Par
21 - Louisville, KY
22 - Dallas-Dallas-Ft. Value, TX
23 - Charlotte, Nc
24 - Cover, Fl
25 - Philadelphia, Par
26 - Saint Louis, Me
27 - Scranton, Par
28 - Lansing, Mi
29 - Madison, WI
30 - Rochester, NY
– 2008 Rank - rankings for the capitals of allergy (pdf)
– capitals of allergy (Web site of AAFA)
- Nordqvist christian close writing
Copyright: Medical notice Today
Not to be reproduced today without permission of the medical notice
- Posted by Vernita Traynham in Uncategorized |
- May 10th, 2008 |
It inspires Pharmaceuticals, Incorporation (Nasdaq: ISPH) announced that its experimentation of phase 3 with nasal spray of epinastine for the treatment of the rhinitis allergic seasonal (SAR) did not meet with preliminary its endpoint.
“our analysis of the total data in this program and the current competitive environment in the rhinitis allergic indicates that the nasal spray of epinastine does not show the potential if to find with our desired profile of the product in the United States,” they had indicated that Christy L. Shaffer, Ph.D., president and CEO of inhale. “we do not planeamos to place nenhuns future resources to this program and will focus in our commercial products and progressing our programs of development high-priority.”
14-day, experimentation randomized, double-blind in 798 patients evaluated two concentrations of epinastine (0,10% and 0.15%) in two comparative volumes of the spray to placebo in the patients with registered SAR during the station of the cedar of the mountain in south central Texas. The groups of the treatment of epinastine had not obtained the meaning statistical comparative to placebo for endpoint preliminary of efficacy of the average change of the line of base for the nasal counting total reflexiva of the symptom (TNSS), defined as the addition of the countings for the nose runny, the nose itchy and sneezing. The drug well- was tolerated and it did not have no interest of security in the experimentation.
In 2006, it inspires definitive exclusive right acquired of gmbH international of Boehringer Ingelheim to become and the nasal spray of epinastine of the market in the United States and Canada for the treatment of the rhinitis.
On It inhales
It inhales is a dedicated biopharmaceutical company products pharmaceutical to the lapsing to discover, to become and commercializing in areas of the illness with significant commercial medical necessities of the potential and unmet. It inhales uses a force of vendas of United States for promotion of AzaSite(R) (solution ophthalmic) of azithromycin 1% for the conjunctivitis bacterial, of Elestat(R) (solution ophthalmic) of HCl of epinastine 0,05% for the conjunctivitis allergic and of Restasis(R) (emulsion ophthalmic) of cyclosporine 0,05% for the dry eye. It inhales it is focused in the areas therapeutic of ophthalmology and respiratory, and is developing products for the dry eye, the fibrosis cystic and glaucoma. Elestat and Restasis are the possessed registadas registered marks for Allergan, AzaSite Incorporation are a possessed registered mark registada for InSite incorporated Vision.
For Diante-Olhando Indications
The indications for ahead-looking at in this release of the notice that becomes related it the expectations and to the opinion of the management are based on preliminary assumptions of the information and the management. Specifically, no guarantee can be made that it inhales it will not need, or it determines in another way, places all the future resources to the nasal program of the spray of epinastine. Moreover, no guarantee can be made regarding inspired the ability to focus in its commercial products and to progress its programs of development high-priority, or the success of its efforts of commercialization or programs of development same if capable to focus its efforts. Such indications for ahead-looking at are citizens to a wide scale of the risks and the uncertainties that could make with that the results differ in material respeitos, including those that if relate to the product development, the income, the expectations of the expenditure and the wage, commercialization of AzaSite, Restasis and Elestat, adverse right of copyright, developments of litigation, adverse developments in the inquiry of commission of seguranas and of exchange of United States (as), the products competitive, the results and to chronometer of experimentations clinics, success of marketing efforts, the necessity for the additional research and to test, are slow in manufacturing, to finance, and the synchronism and the index of the decisions made for authorities regulatory, including the administration of the food and the drug of United States. A additional information regarding the factors that could affect inhaled resulted is enclosed inside inspired fillings with as. It inhales does not undertake no obligation to liberate the results of all public the revisions to these indications for ahead-looking at that they can be made to reflect of this events or circumstances after the date.
It inspires Pharmaceuticals
It sees the information of the drug in AzaSite, Restasis
- Posted by Vernita Traynham in Uncategorized |
- May 9th, 2008 |
The 50 million American esteem suffer from the miseries of allergies, with the reactions allergic that they involve the eyes a common complaint. For many, the symptoms of allergies of the eye can thus be bothering and irritating that intervene with the work performance, they hinder the leisure-time and they exhibit activities, and curtail vacation.
To help to sufferers of allergy better to understand and to control the condition, asthma and the foundation of allergy of America (AAFA), main the patient organization for peoples with asthma and allergies, are offering a free educational brochure intitled of the “health and allergies eye.”
“approximately four percent of sufferers of allergy allergy tries allergies of the preliminary eye as its, caused frequent for many of the same triggers that allergies of indoor/outdoor such as the pollen, the mold, or dander of the esteem animal,” says the Tringale microphone, director of the external cases, AAFA. “this brochure offers the useful information in as allergies of the eye occurs, common signals and symptoms, and practical advice in as to treat and to hinder allergies it eye.”
The brochure, supported for WET lenses of 1(R) contact(R) of the type of DAY ACUVUE, also includes smart strategies of the station of allergy for wearers of the lens of contact of the nation the 40 million, a group for who eye allergies can use original problems.
of “sufferers allergy that they consume the contact lenses that you use per two weeks or more they can try discomfort and symptoms such as itching ocular, tearing, and redness, because allergens and others irritants can construct above in the lenses on the time,” explains optometrist York-base new Susan Resnick, O.D., F.A.A.O. “disinfectants chemical and the used condoms in some systems of the care of the contact lens also can cause the ocular affliction.”
To help to minimize these symptoms, wearers of the contact lens can limit its time consuming during the station of allergy, but the Dr. Resnick says that it does not have no necessity to interrupt the consuming of the contact lens during the station of allergy.
the “studies had shown that the only use contacts the daily dismissable lenses that you play moved away in the end from the day - she can be healthful and a more comfortable option for many peoples with allergies of the eye,” writes down. “putting in a clean, cool lens each day, the contacts one-day minimize the potential for the accumulation of allergens and irritants that they can frequent accumulate with repeated use of the same pair of the lenses.”
In one study1 to three-year that it compares the clinical performance of daily dismissable materials (1 DAY ACUVUE(R) marks contact lenses) with the that one of conventional daily-consuming lenses, wearers single-uses of the lens had told few symptoms of redness, vision cloudy, and grittiness; at the same time, they had told to the vision best and the total satisfaction, and had had few deposits of the surface of the lens, complications, or visits of the doctor not programmed.
To help to sufferers of allergy that they would like to start to consume or to continue consuming contact lenses, the brochure, together with a free certificate of the experimentation-pair for WET lenses of 1(R) contact(R) of the type of DAY ACUVUE, is also available in http://www.acuvue.com/seasons.
“when expense in a daily dismissable base, 1 DAY ACUVUE WET(R) can supply the improved comfort two is of three patients who suffer from discomfort soft associate with allergies during the consuming of the lens of contact compared with those lenses two-week consuming,” the Dr. Resnick says.
the WET lenses of 1 contact(R) of the type of DAY ACUVUE are available for the lapsing only for the correction of the vision. A professional of the care of the eye will determine if the contact lenses are right for individual patients. Although rare, the serious problems of the eye can become. To help to prevent these problems, the patients must follow the programming of the consuming and the replacement and the instructions of the lens-care supplied by its doctor of the eye. The individuals do not have to consume lenses will have one discomfort of the eye of the infection or the experience of the eye, to tear extreme, changes of the vision, redness, or other problems of the eye. If one of these circumstances to occur, must contact its doctor of the eye immediately.
Not enclosed professional taxes of exam it and the rabbet. Valid when the sources only to last.
1 Solomon OD, freeman MJ, et al. “a perspective study to 3-year of the clinical performance of daily dismissable lenses of contact it compared with the frequent replacement and the conventional daily lenses of contact of the consuming.” CLAO J, 1996; 22:250-7.
ACUVUE(R) and 1 DAY ACUVUE(R) WET(R) are registered marks of the care of Johnson & vision of Johnson, Inc..
Johnson and Johnson
http://www.jnj.com
- Posted by Vernita Traynham in Uncategorized |
- May 7th, 2008 |
Sufferers of asthma had been able to also stop the expensive energy wasting and the money in interventions work-intensive or to start exempted of the dust of the house, in accordance with a new revision of the studies.
“we can conclir with confidence that does not have no necessity to buy expensive vacuum cleaners of p30 or the covers of mattress or to use chemical methods of meeting to the espana house mites, because these treatments do not work,” said author Peter Gotzsche of the linking, M.D.
Some peoples with asthma are allergic to the known very small arthropods oito-eight-legged as mites of the dust of the house and allergens of these mites can bring in attacks of asthma. Unhappyly, the revision 54-study of 3.000 patients of asthma finds that no chemical or physical intervention to reduce the exposition to the mites of the dust of the house is efficient.
Gotzsche, director of the center nordic of Cochrane in Copenhaga, Denmark, said that the thousands of specialists speculating on this problem and has attemped all the luck of interventions per many years, but it still did not find the reply right.
Gotzsche and the colleagues had lead its first systematic revision in 1998; diverse times had brought up to date its revision with new studies.
The studies, that had approximately varied of two weeks the two years of duration, had used a variety of interventions. Some studies had used chemical products to kill mites, when others had used interventions physicists such as to lock up mattresses and rests in the covers that the mites cannot start completely. Other studies had been called to wash frequent of linhos of bed in the hot water or the bleach; cushions beating outside; e removing the toys, the plants and furniture of a rest.
Although he seems counterintuitive that such efforts intensive to control mites of the dust were unproductive, findings consistent and is opened.
“if you are wanting to know because she is that the covers of mattress and the other strategies are not efficient, the probable reply is that all these treatments sufficiently do not have a great effect in the occurrence of allergens of the mites of the dust of the house,” said Gotzsche. “the level of allergens thus is raised in the majority of repousos that that remains later that the treatment must highly sufficiently still cause attacks of asthma.”
It said that exactly the very low concentrations of allergen can affect the bronchial affliction between sensible individuals, and the majority of repousos houses many mites and allergens of the mite. Beyond, the mite-sensible individuals are frequent sensible to others allergens, in way that elimination successful of only allergen can have limited the benefit in better.
Some of the enclosed studies had gotten 50 reductions of more than percent, and some consideravelmente more, but they are even to reduce allergens ambient for 90 percent are insufficient, said Gotzsche. Before interventions can work, you must reduce allergens distant of the one more than you can get with interventions studied thus distant.
Gotzsche is critical of 2007 guidelines of United States of the national program of the instruction and the prevention of asthma, whose the plant of action of asthma for patients recommends interventions such as to lock up mattresses and rests in the special covers dust-proof, and of leves of laudering, the blankets and the toys fulled in the hot water each week.
the “revisions and guidelines must reflect the facts,” said. “it is difficult, perhaps, to carry through that we cannot really make any thing, but is not no evidence there to support these guidelines and are deceptive. It is on the start of specialists of the time that becomes honest with patients.”
Gotzsche described to testify efforts to introduce in the market $10,000 vacuum cleaners of p30 to the vulnerable parents of the children with asthma. These machines were not exactly better of the one than cheap if in removing the dust, it it said.
the “parents are deceived to the times for tradesmen reckless, but it is better not to waste the money in interventions that they do not work,” it said.
Noreen Clark, Ph.D., professor of the public health in the university of Michigan, described this as an important revision. Clark, who also serves as the national director of the program for the allies wooden of the foundation of Robert Johnson of meeting to the program of asthma, said that when a doctor recommends a strategy of the management that was difficult of if to carry through and did not produce the result desired, the patient loses the confidence in other efficient things the doctor recommended.
“the patient treatment and to advise must focus in some things that the samples of the evidence will be significant in starting the illness under the control,” said Clark. “this study it suggests that to try to reduce the exposition to the mites of the dust being covered mattresses, using ionizers, washing the bedding in high temperatures, and thus for ahead, will not help and does not have to be in the list.”
The article was adaptou today for Medical Notice of the release of the original press.
Podcast: The library of Cochrane is liberating one podcast in this revision, available to the public in the day of the publication, in http://www.cochrane.org/podcasts/
The contribution of Cochrane is an organization nonprofit, the independent International that produce and disseminates systematic revisions of interventions of the care of health and promotes the search for the evidence in the form of clinical experimentations and other studies of interventions. Visit http://www.cochrane.org/ for more information.
PC Of Gotzsche, Johansen HK. It shelters measures of control of the mite of the dust for asthma (revision). Database of Cochrane of systematic revisions 2008, edition 2.
Source: Smooth Esposito
Center for the advance of the health
- Posted by Vernita Traynham in Uncategorized |
- May 5th, 2008 |
The research in correlations between allergies and development of tumours - and the possible benefits for the future treatments of cancer - changedded one finally disciplines established of the research in its proper right. That age the conclusion in symposium international of AllergoOncology, that occurred in Vienna in the weekend. Organiser of symposium, Prof. Jensen-Jarolim, was extremely happy with the event, that was taken care of close on 90 doctors and scientists on to 10 different countries. This field of fascinating research, that occurred in the establishment with sustentation of deep austrian FWF of science, was also honored with its first article of revision in the international periodical “allergy”.
Although the scientists are cliente of the phenomenon for on 50 years, she is only on last the three of that it has been a dedicated field of research that looks at in the influence of reactions allergic in the development of tumours. Known as AllergoOncology, this disciplines looks at the ways that the reactions allergic can inhibit the growth of tumours of cancer.
This field of research was established by Prof. Erika Jensen-Jarolim, head of the department of pathophysiology in the medical university of Vienna. Its work in establishing AllergoOncology as a distinct field of the medical research started diverse years has as part of a functioning of the project for deep austrian FWF of science.
Synergy & Symposium
International Symposium of AllergoOncology of the last weekend in Vienna, according to being organized by Prof. Jensen-Jarolim, since whom an international host of immunologists and oncologists with potential the ideal chance to argue synergies in its work. The wide propagation of the topics covered in the event included a presentation for Prof. Chris Parish of the school of John Curtin of the medical research in Australia. It consulted to a project during that the resistance determined tumours quimicamente induced was obtained in a model of the rat through the administration of the white stacks of blood, that they are associates also with allergies.
“uniform if the results of the animal models could not directly be transferred to the human beings, projects as Prof. Parish still demonstrates to the enormous potential therapeutic of AllergoOncology,” Prof. Jensen-Jarolim of the commentaries.
One another project was presented for the Dr. Manuel Penichet, university of California, that was carried through in the cooperation with the teams lead for College of Prof. Hannah Gould, the king, for London, and Prof. looked Jensen-Jarolim to fight cancer of chest. To make this, the team used a characteristic key of antibodies special that antibodies of IgE is jointly responsible for reactions allergic -. These antibodies have a effect highly reactive and long-lasting of meeting to proteins these the classrooms of the body as not desired. This reply of IgE it can also accurately be directed of meeting to the structures of the protein in determined stacks of tumour. This characteristic is being used for the team and can exactly be enhanced making specific adjustments to the structure of antibody.
However, Prof. Jensen-Jarolim also felt that the potential of AllergoOncology crticamente must scrutinised during symposium, and a debate that involves a panel of specialists lead by journalist that of the science of life Johanna Concede-Geissler it supplied the ideal solution. Prof. Jensen-Jarolim explains: “to assure a research field he survives in the stated period, us we need to have the peoples who are made use to be critical and us we must put in consistent verifications of the place. This is because participants of symposium had also been presented with data of a study viennese on of 22.000 patients of cancer, that they had been incapable to identify to all the general linking between mortality and the concentration of IgE in serum, except in the example of lymphoma and leukaemia it. The reasons behind of this will need to be analyzed more more.”
A revision article that unveiled exclusively in advance in the weekend showed only how much progress has been made already to make the AllergoOncology a field established in the medicine and science international.
The article must be officially published in the international periodical “allergy” in some weeks. Of perspective of the FWF, symposium and the advanced article demonstrate that to recently supply to the advanced sustentation research fields interdisciplinary emergent such as AllergoOncology really makes the direction.
The full program of symposium international of AllergoOncology can be found in: http://www.allergooncology.org.
Fr PathophysiologieMedizinische Universitt WienInstitut
Deep Austrian FWF Of Science
- Posted by Vernita Traynham in Uncategorized |
- May 3rd, 2008 |
Perrigo Company (Nasdaq: PRGO; TASE) announced that it received aprova0 final from the administration of the food and the drug from United States to manufacture and to introduce in the market the verbal solution of hydrochloride of Cetirizine of the children (OTC) to over-the-counter (allergy) and the verbal solution of hydrochloride of Cetirizine of the children (Hives-Relevo), 1mg/mL.
The product will be introduzdo in the market under labels of the type of store and is comparable to the verbal solution of Zyrtec of the children of consuming Healthcaredo of McNeil (R), 1mg/mL, indicated for allergy indoor and to the outdoors and hives the relief. In accordance with given of Wolters Kluwer, vendas of the type for the original version of the force of the lapsing of the product for last the 12 months that finish December 2007 was approximately $80 million.
President of Perrigo and CEO Joseph C. indicated Papa, “this aprova0 reflects our strategy to be first to introduce in the market with the important products that they make healthcare of the quality more affordable for our customers.”
The company waits to start to send the product immediately.
Perrigo Company is main a global supplier of healthcare that it develops, manufactures and distributes pharmaceuticals to over-the-counter (OTC) and of the nutritional lapsing, products, the active ingredients pharmaceutical (API) and the products of consumer. The company is the manufacturer the greater of the pharmaceutical world of products of OTC for the market of the type of store. The preliminary markets and the positions of the company of easinesses of manufacturing are the United States, Israel, Mexico and the Joined Kingdom. Perrigo visit in the InterNet (http://www.perrigo.com).
Note: Determined indications in this release of the press for ahead- they are looking at indications inside of meaning of the section 21E of the act of exchange of seguranas of 1934, as amended, and are citizens to the safe port created in this way. These indications become related it the future events or the future financial performance of the company and become involved the known risks and unknown, the uncertainties and the other factors that can make with that the real results, the levels of the activity, the performance or the accomplishments of the company or its industry are materially different of those expressed or implied by all the indications for ahead-looking at. In some cases, ahead-to look at indications it can be identified by the terminology as “it can,” “,” “could,” “,” “if,” “it waits,” “plant,” “anticipate,” “intend,” “believe,” “estimative,” “predict,” “potential” or to another comparable terminology. The company based these indications for ahead-looking at in its current expectations, assumptions, estimates and projections. When the company to believe these expectations, the assumptions, the estimates and the projections are reasonable, such indications for ahead-looking at are only predictions and involve the known and unknown risks and uncertainties, many of that are beyond the control of the company. These and other important factors, including those argued under of “factors risk” in the form 10-K of the company per the year had finished June 30, 2007, as well as the subsequent fillings of the company with commission of seguranas and of exchange, they can make with that the real results, performance or accomplishments differ materially from those expressed or implied by these indications for ahead-looking at. The indications for ahead-looking at in this release of the press are only made as of the date of this, and unless required in another way for applicable laws of seguranas, the company the intention or obligation contradicts all to bring up to date or to revise any indications for ahead-looking at, if in consequence of the new information, future events or in another way.
Perrigo Company
http://www.perrigo.com
Information of the drug of the sight in Zyrtec
- Posted by Vernita Traynham in Uncategorized |
- May 1st, 2008 |
In contrast with the world of high-tech, the community of biotech of Israel is populated with the women who lead the company life-in change in millennium new. They are CEOs and expert of the business development that sniff for is of the possibilities of the new technology of the Israeli academy and they bring them then to the life.
One of these women is Anat Eitan, to founder and CEO of two new departures AllergyFight and VacciGuard of biotech. After to work in pharmaceuticals of Teva in the innovative R&D per 12 years, “I learned all needed I to know for drugs becoming,” Eitan I say ISRAEL21c.
Before changedding an enterprising one it was the CEO of Metabogal (now Protalix), and worked as a consultant in technology transfer.
Recognizing a chance in the research of Prof. Irun Cohen of the institute of Weizmann of science, the last year in advance Eitan established VacciGuard inside of the accelerator of the risk of Misgav.
The company, that it intends to develop vaccines of meeting to the illnesses such as cancer of lung, could improve the probabilities for the 350,000 Americans who die of cancer of lung each year.
Now in the period of training to establish the test-$$$-CONCEITO in the animal models for occidental vaccines of cancer of the virus and lung of Nile, VacciGuard, if it passed clinical experimentations, it could open above of an entire new world for the treatment of the illness.
“VacciGuard allows the immune system of the body to efficiently answer to antigens non-non-immunogenic, such as peptides or polysaccharides, expressed or in pathogens or the fabrics of cancer,” say Eitan. “these antigens generally do not activate the immune system to generate antibodies efficient of meeting if.”
Or either the technology of VacciGuard converts strong weak antigens into immunogens and cra notvelmente efficient vaccines, it explain.
The vaccine of the lung-lung-cancer of VacciGuard would be managed the surgery after and chemotherapy of cancer when the doctor removes the tumor preliminary, where the survival of the point of cancer of lung is consideravelmente low - approximately 15 percent on five years. The re-occurrence of cancer is very probable at this moment and Eitan waits that VacciGuard can stop cancer in its tracks.
Pathogens could also work of meeting to others such as the meningitis and the pneumonia.
Its second AllergyFight company, supported for the incubator of the technology of Ashkelon, was initiated in 2007 been slow.
More good that it masks the symptoms of allergies, that is as the majority of drugs works today, technology of AllergyFight, based on the research of Prof. Israel Pecht of the Weizmann, and Prof. Anna Erdei of the university of Budapest, Hungria, is established in an agent modifying of the illness, more good that in that alliviates only symptoms.
Allergies afflict approximately 40-50 million peoples in And U. each year and between them approximately 36 million suffers also from the rhinitis allergic seasonal, or the fever of the hay. Beyond the cause of allergies of the misery, they can also lead to the circumstances life-threatening. A safe and efficient drug for allergies hindering and of treatment is very so necessary.
Eitan is happy to make its part, and recognizes a field playing entrepreneurial fort in Israel, opens it it the men and to the women. “to be an entrepreneur he is something in my nature,” says. “I always felt that I would changed one.”
With the two children of its proper ones, he compares the development of new drugs childrearing. “to make examination of something of a period of training of start and to bring it it maturation, I v the connection between my work and the spirit feminine.”
E if Eitan did not work in drugs if becoming of the notice, it could fcilmente be seen to dislocate in the life of a world-traveller - a luck of the anthropologist who lives enters one tribe in deep Africa or in the forest in some place.
Perhaps in its following life?
http://www.israel21c.org
- Posted by Vernita Traynham in Uncategorized |
- April 30th, 2008 |
On five the 13 million million sufferers of the fever of the hay through Gr Britain could make examination of improper medicines, to put its health in the risk. Real the pharmaceutical society of (RPSGB) is stimulating the peoples who try the symptoms of the fever of the hay to visit its community that pharmacist after the new research disclosed that the public frequent misdiagnose the circumstance and does not start the correct treatment.
The rhinitis allergic, known as the fever of the hay, is a circumstance that is caused by the pollen of specific plants seasonal, of chemical products airlift and of particles of dust. Sneezing is characterized generally by the symptoms of the nose, runny and of the eyes itching *.
An examination, commission for the RPSGB, found that ones 73% disconcerting of the peoples who try these symptoms they do not look the medical advice before selecting a treatment. Moreover, the research discloses to the harmful effect the fever of the hay that can have in the quality of sufferers ‘ of life. The research finds that almost 40% of sufferers of the fever of the hay if become irritable, and one third experience that sleeps difcilmente. Worryingly, 29% have difcilmente to concentrate and 14% said its symptoms affected its ability to read - findings particularly that they could have significant implications for children and students of school, as the station of the fever of the hay clashes with time of exam it.
More than one in 10 said embarrassed on its appearance and prevents of socialising, when if in 20 sufferers of the fever of the hay to say that they prevent to leave the rest because of its condition.
David Pruce, director of RPSGB of the practical one & the improvement of quality, says:
“the results of the examination demonstrate to the impacts a condition clearly as the fever of the hay can have in lives of the peoples, with the millions that suffer desnecessariamente. Pharmacists highly professional and expert is trained of health in the medicines - the fever of the hay can play a significant paper in the management of allergies including.
“the numbers of the peoples do not look the advice on its symptoms are surprising. It has a great choice of the available products of anti-anti-allergy and pharmacists is placed well to recommend in what it is better for the individual. Pharmacists tins helps to populate recognizes symptoms, identifies triggers of allergy and selects products appropriate. Pharmacists can also suggest the changes of life-style that they can bring the relief of the fever of the hay and recommend potential patients on side-effects of the medicines that can make examination.
“pharmacies situated in the places where the peoples live, works and buys and is opened in convenient hours without the necessity to make a nomination.”
Notes
Fever Of The Hay
The rhinitis allergic, known as the fever of the hay, is a condition that is caused by the pollen of the specific plants seasonal, of the chemical products airlift and of the particles of dust, that only occur for times of the year, in the peoples who are allergic to these substances. The stacks in the lining of the nose and the eyes liberate histamine and the other chemical products when they come in the contact with pollen. This cause inflammation in the nose (rhinitis) and the eyes (conjunctivitis). The fever of the hay is characterized generally by the nose sneezing, runny and for the eyes itching.
* The symptoms of the fever of the hay are wide-ranging. They can include the following one:
- itching of the nose, the mouth, the eyes, the throat, the skin, or the some area displayed to allergen
- nose runny
- eyes wetting and/or plugged above of the ear canals.
- sneezing
- I smell damaged
- congestion nasal
- throat sore
- wheezing
- conjunctivitis
- fever
- coughing
- headache
- it tires
- irritability
Real the pharmaceutical society of Gr Britain
Real the pharmaceutical society of Gr Britain (RPSGB) is the professional body and regulatory for pharmacists in England, Scotland and wales. It also regulates technician of pharmacy in a voluntary base, that if waits to become statutory under the anticipated legislation. The preliminary objectives of the society are to lead, to regulate, to develop and to represent to the profession - of pharmacy.
Research
The research was carried through by YouGov between 02-04 April 2008, interviewing 1981 547 peoples including sufferers of the fever of the hay. The population of the GB of adults 18+ is (in accordance with ONS) 46.158.100. Consequently the number of sufferers of the fever of the hay in Gr aged Britain 18 years of age and above (27.59%) is 12.735.019. Of these, 41,95% agreed that they can misdiagnosed its condition, that equals the 5.342.340. The full results of research are available in the order.
Real the pharmaceutical society of Gr Britain
« Previous Page